{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:24:42Z","timestamp":1791217482112,"version":"4.1.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study sought to determine the level of understanding and opinion among rheumatologist and pulmonologists regarding risk factors, diagnostic approach and treatment of RA-associated interstitial lung disease (RA-ILD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted an international electronic survey of rheumatologists and pulmonologists utilizing two separate Redcap-based surveys with questions on the epidemiology, workup and management of RA-ILD as well as ILD screening questions using case-based scenarios directed at rheumatologists. The survey also collected demographic data on participants including their practice setting, years in practice and country of practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We received a total of 616 responses (354 rheumatologists and 262 pulmonologists) from six continents. There were significant differences in responses between pulmonologists and rheumatologists in estimated prevalence and mortality, risk factors for the development of ILD in RA and medications that are effective or should be avoided. Rheumatologists were much less likely to consider assessment for ILD in high risk, asymptomatic patients compared with high-risk patients with either symptoms or exam findings suggestive of ILD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our study brought to light the variability in disease assessment and clinical practice among providers caring for patients with RA-ILD and indicate that greater education is needed to optimize clinical decision making in the risk assessment, screening and treatment of RA-ILD. Research questions that address appropriate screening and treatment strategies for RA-ILD will be valuable for rheumatologists given their central role in the overall health and lung health of patients with RA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab552","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T19:14:19Z","timestamp":1625858059000},"page":"1459-1467","source":"Crossref","is-referenced-by-count":23,"title":["The attitudes and practices of physicians caring for patients with rheumatoid arthritis-associated interstitial lung disease: an international survey"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5488-4874","authenticated-orcid":false,"given":"Joshua J","family":"Solomon","sequence":"first","affiliation":[{"name":"Department of Medicine, National Jewish Health, Denver, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J","family":"Swigris","sequence":"additional","affiliation":[{"name":"Department of Medicine, National Jewish Health, Denver, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[{"name":"Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik University of Heidelberg"},{"name":"German Center for Lung Research, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Polke","sequence":"additional","affiliation":[{"name":"Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik University of Heidelberg"},{"name":"German Center for Lung Research, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri","family":"Aronson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6467-7422","authenticated-orcid":false,"given":"Anna-Maria","family":"Hoffmann-Vold","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F","family":"Dellaripa","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"2022041112483631300_keab552-B1","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","article-title":"The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study","volume":"73","author":"Cross","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022041112483631300_keab552-B2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-3-319-68888-6_4","volume-title":"Lung disease in rheumatoid arthritis","author":"Demoruelle","year":"2018","edition":"1st edn"},{"key":"2022041112483631300_keab552-B3","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1164\/rccm.201004-0622OC","article-title":"Rheumatoid arthritis-interstitial lung disease-associated mortality","volume":"183","author":"Olson","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2022041112483631300_keab552-B4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/archinternmed.2007.59","article-title":"Progressive preclinical interstitial lung disease in rheumatoid arthritis","volume":"168","author":"Gochuico","year":"2008","journal-title":"Arch Intern Med"},{"key":"2022041112483631300_keab552-B5","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2022041112483631300_keab552-B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2017.04.002","article-title":"Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease","volume":"127","author":"Natalini","year":"2017","journal-title":"Respir Med"},{"key":"2022041112483631300_keab552-B7","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3899\/jrheum.171315","article-title":"Rheumatoid arthritis\u2013interstitial lung disease in the United States: prevalence, incidence, and healthcare costs and mortality","volume":"46","author":"Raimundo","year":"2019","journal-title":"J Rheumatol"},{"key":"2022041112483631300_keab552-B8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1185\/03007990903422307","article-title":"Societal cost of rheumatoid arthritis patients in the US","volume":"26","author":"Birnbaum","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"2022041112483631300_keab552-B9","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"2022041112483631300_keab552-B10","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1007\/s12325-019-01086-2","article-title":"The design and rationale of the trail1 trial: a randomized double-blind phase 2 clinical trial of pirfenidone in rheumatoid arthritis-associated interstitial lung disease","volume":"36","author":"Solomon","year":"2019","journal-title":"Adv Ther"},{"key":"2022041112483631300_keab552-B11","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","article-title":"Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database","volume":"71","author":"Meier","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2022041112483631300_keab552-B12","doi-asserted-by":"crossref","first-page":"1901760","DOI":"10.1183\/13993003.01760-2019","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation","volume":"55","author":"Kreuter","year":"2020","journal-title":"Eur Respir J"},{"key":"2022041112483631300_keab552-B13","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1080\/03007995.2019.1647040","article-title":"Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management","volume":"35","author":"Wijsenbeek","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"2022041112483631300_keab552-B14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-3-319-68888-6_4","volume-title":"Lung disease in rheumatoid arthritis","author":"Demoruelle","year":"2018"},{"key":"2022041112483631300_keab552-B15","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3899\/jrheum.101261","article-title":"High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis","volume":"38","author":"Aubart","year":"2011","journal-title":"J Rheumatol"},{"key":"2022041112483631300_keab552-B16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00296-004-0472-y","article-title":"Pulmonary involvement in rheumatoid arthritis","volume":"25","author":"Bilgici","year":"2005","journal-title":"Rheumatol Int"},{"key":"2022041112483631300_keab552-B17","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1136\/thx.56.8.622","article-title":"Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests","volume":"56","author":"Dawson","year":"2001","journal-title":"Thorax"},{"key":"2022041112483631300_keab552-B18","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1164\/ajrccm.156.2.9609016","article-title":"Interstitial lung disease in recent onset rheumatoid arthritis","volume":"156","author":"Gabbay","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"2022041112483631300_keab552-B19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00296-006-0234-0","article-title":"Radiological and functional assessment of pulmonary involvement in the rheumatoid arthritis patients","volume":"27","author":"Kanat","year":"2007","journal-title":"Rheumatol Int"},{"key":"2022041112483631300_keab552-B20","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/art.1780391014","article-title":"Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities","volume":"39","author":"Saag","year":"1996","journal-title":"Arthritis Rheum"},{"key":"2022041112483631300_keab552-B21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jbspin.2004.02.001","article-title":"Correlations between high-resolution computed tomography of the chest and clinical function in patients with rheumatoid arthritis. Prospective study in 75 patients","volume":"72","author":"Zrour","year":"2005","journal-title":"Joint Bone Spine"},{"key":"2022041112483631300_keab552-B22","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1136\/ard.54.4.308","article-title":"High resolution computed tomography of the lung in lifelong non-smoking patients with rheumatoid arthritis","volume":"54","author":"Hassan","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"2022041112483631300_keab552-B23","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00296-010-1665-1","article-title":"The clinical significance of HRCT in evaluation of patients with rheumatoid arthritis-associated interstitial lung disease: a report from China","volume":"32","author":"Zou","year":"2012","journal-title":"Rheumatol Int"},{"key":"2022041112483631300_keab552-B24","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1378\/chest.127.6.2019","article-title":"Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease","volume":"127","author":"Lee","year":"2005","journal-title":"Chest"},{"key":"2022041112483631300_keab552-B25","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1001\/archinte.168.15.1718","article-title":"Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug","volume":"168","author":"Saketkoo","year":"2008","journal-title":"Arch Intern Med"},{"key":"2022041112483631300_keab552-B26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4236\/ojra.2012.23011","article-title":"Open-label, pilot study of safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia","volume":"02","author":"Matteson","year":"2012","journal-title":"Open J Rheumatol Autoimmun Disord"},{"key":"2022041112483631300_keab552-B27","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"2022041112483631300_keab552-B28","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2022041112483631300_keab552-B29","doi-asserted-by":"crossref","first-page":"2000337","DOI":"10.1183\/13993003.00337-2020","article-title":"Methotrexate and rheumatoid arthritis associated interstitial lung disease","volume":"57","author":"Juge","year":"2021","journal-title":"Eur Respir J"},{"key":"2022041112483631300_keab552-B30","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/rheumatology\/keaa327","article-title":"Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study","volume":"60","author":"Ibfelt","year":"2021","journal-title":"Rheumatology"},{"key":"2022041112483631300_keab552-B31","doi-asserted-by":"crossref","first-page":"e028466","DOI":"10.1136\/bmjopen-2018-028466","article-title":"Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts","volume":"9","author":"Kiely","year":"2019","journal-title":"BMJ Open"},{"key":"2022041112483631300_keab552-B32","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3389\/fmed.2019.00246","article-title":"The role of the multidisciplinary evaluation of interstitial lung diseases: systematic literature review of the current evidence and future perspectives","volume":"6","author":"Furini","year":"2019","journal-title":"Front Med"},{"key":"2022041112483631300_keab552-B33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/rheumatology\/keq233","article-title":"The impact of rheumatological evaluation in the management of patients with interstitial lung disease","volume":"50","author":"Castelino","year":"2011","journal-title":"Rheumatology"},{"key":"2022041112483631300_keab552-B34","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3899\/jrheum.150966","article-title":"A multidisciplinary evaluation helps identify the antisynthetase syndrome in patients presenting as idiopathic interstitial pneumonia","volume":"43","author":"Chartrand","year":"2016","journal-title":"J Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab552\/40505319\/keab552.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/4\/1459\/43355887\/keab552.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/4\/1459\/43355887\/keab552.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T12:49:35Z","timestamp":1649681375000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/4\/1459\/6321473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,7,14]]},"published-print":{"date-parts":[[2022,4,11]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab552","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2021,7,14]]}}}